New and More Efficient Method to Make Insulin Cheaper

With more and more people getting diabetes and many of them eventually using insulin, it would be very important to reduce the cost of insulin. The group's results have now been published in the open access online research magazine Microbial Cell Factories. With this publication, all information is freely accessible for everyone and is not subject to patent law.

The researchers wanted to develop a new procedure to increase the yield of an insulin precursor from which the actual insulin can be obtained, and in this way reduce costs. They found the yeast Pichia pastoris and modified the cells so that they produce the building block for insulin while growing on a special medium. The results were highly gratifying. "With our procedure, Pichia pastoris delivers high yields -- twice as much as known before," says Ursula Rinas. "Already with few cells it is possible to produce a lot of the insulin precursor."

In the early 1980s, insulin was the first recombinant product approved by the FDA for human application. Today, human insulin is produced as recombinant protein, using two major routes. One route involves the production of the insulin precursor using the bacterium Escherichia coli as expression host with complex subsequent isolation, solubilization and refolding procedures. The other route involves the well-known baker's yeast Saccharomyces cerevisiae. The advantage of the latter route lies in the secretion of a soluble insulin precursor into the culture supernatant, making it easier for isolation and chemical modification. The newly described method from Ursula Rinas and her group also uses this route. The isolation of the precursor from the culture supernatant is only followed by enzymatic finishing. Insulin produced with this new method can be used normally and is identical to human insulin.

For most people in developing countries medicine is too expensive. The purchasing of insulin in those countries is often cost prohibitive. Another problem is patent law that makes it impossible to recreate medicine and sell it at low prices. Once a patent has expired, as is the case with insulin, the so-called generic drugs can be produced cheaply. Unfortunately, emerging nations very often lack the insider knowledge to produce those generics.

Original article: Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microbial Cell Factories, May 2010